Review of Shukla, Evans, et al. (2016) **_Development of a RNA-Seq Based Prognostic Signature in Lung Adenocarcinoma_**

 

**Track 3:** Cancer Biomarkers Discovery

**Paper Link: **<https://academic.oup.com/jnci/article/109/1/djw200/2905970>

**Authors:** Irina Andruishchenko, Oluwatosin Owolabi, Balqees Fiez Mohammad Mansour,  Nusrat Afrin

**GitHub Link:**

**LinkedIn Post link: <https://www.linkedin.com/posts/nusrat-afrin-0686b716b_oncology-cancerabrgenomics-biomarkers-activity-7238275121973489664-imFu?utm_source=share&utm_medium=member_desktop>**

 

 

**Introduction**

Lung cancer, a leading cause of cancer-related deaths in the United States, is particularly lethal when it manifests as lung adenocarcinoma. In a groundbreaking study, researchers have developed the first RNA-seq prognostic signature for this form of lung cancer, presenting a significant advancement in personalized treatment strategies. This novel prognostic tool was derived from a comprehensive analysis of RNA sequencing data from the TCGA lung adenocarcinoma cohort.

**Study Design**

<!--[if gte vml 1]><v:shapetype
 id="_x0000_t75" coordsize="21600,21600" o:spt="75" o:preferrelative="t"
 path="m@4@5l@4@11@9@11@9@5xe" filled="f" stroked="f">
 <v:stroke joinstyle="miter"/>
 <v:formulas>
  <v:f eqn="if lineDrawn pixelLineWidth 0"/>
  <v:f eqn="sum @0 1 0"/>
  <v:f eqn="sum 0 0 @1"/>
  <v:f eqn="prod @2 1 2"/>
  <v:f eqn="prod @3 21600 pixelWidth"/>
  <v:f eqn="prod @3 21600 pixelHeight"/>
  <v:f eqn="sum @0 0 1"/>
  <v:f eqn="prod @6 1 2"/>
  <v:f eqn="prod @7 21600 pixelWidth"/>
  <v:f eqn="sum @8 21600 0"/>
  <v:f eqn="prod @7 21600 pixelHeight"/>
  <v:f eqn="sum @10 21600 0"/>
 </v:formulas>
 <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
 <o:lock v:ext="edit" aspectratio="t"/>
</v:shapetype><v:shape id="image1.png" o:spid="_x0000_s1026" type="#_x0000_t75"
 style='position:absolute;left:0;text-align:left;margin-left:109.5pt;
 margin-top:95.95pt;width:279.35pt;height:252.25pt;z-index:251658240;
 visibility:visible;mso-wrap-style:square;mso-height-percent:0;
 mso-wrap-distance-left:9pt;mso-wrap-distance-top:9pt;
 mso-wrap-distance-right:9pt;mso-wrap-distance-bottom:9pt;
 mso-position-horizontal:absolute;mso-position-horizontal-relative:text;
 mso-position-vertical:absolute;mso-position-vertical-relative:text;
 mso-height-percent:0;mso-height-relative:margin'>
 <v:imagedata src="file:///C:/Users/User/AppData/Local/Temp/msohtmlclip1/01/clip_image001.png"
  o:title=""/>
</v:shape><![endif]--><!--[if !vml]-->![](file:///C:/Users/User/AppData/Local/Temp/msohtmlclip1/01/clip_image002.gif)<!--[endif]-->The study identified **96 genes** with statistically significant prognostic associations, including five long non-coding RNAs (lncRNAs). Notably, a four-gene signature which features the lncRNA LINC00941 emerged as a robust prognostic marker. This four-gene signature was validated through its strong association with both metastasis-free survival and overall survival in additional TCGA cases as well as in an independent institutional cohort. The significance of this signature lies in its potential to be rapidly incorporated into RNA-seq clinical sequencing programs, thereby allowing for tailored management of early-stage lung adenocarcinoma.

 

 
**Key Findings**

Early-stage lung adenocarcinoma is characterized by poorer survival outcomes compared to other cancers. Current treatment decisions, including adjuvant chemotherapy, are largely based on clinical criteria such as tumor size. However, the study highlights the need for more sophisticated, genomic-guided approaches. While mutation identification has been crucial for targeted therapies in metastatic cancer, outcome variability within mutation cohorts remains a challenge. The ongoing trials, including ALCHEMIST and various national basket trials, aim to address these issues by exploring comprehensive genomic testing. RNA-seq offers several advantages over traditional microarray technologies, including detecting low-abundance transcripts and providing comprehensive genomic alteration information. These capabilities make RNA-seq a superior platform for clinical applications, particularly for detecting noncoding RNA and understanding tumor biology.

** **

**Overview**

To summarize, the study utilized data from **The Cancer Genome Atlas (TCGA)**, dividing it into a training cohort and a validation cohort in a chronological manner to develop and test the prognostic model. Approximately 15,000 genes were analyzed in the training cohort, leading to the identification of 96 genes with significant prognostic associations. A four-gene signature was then developed using the multivariable Cox model. The risk score calculation was applied to different cohorts, and the prognostic significance was analyzed using multivariable Cox models and Kaplan-Meier analysis, ensuring robust statistical validation of the findings. Despite its potential, the study has limitations, including the retrospective nature of the data and variability in bioinformatics parameters.  Additionally, therapy was neither randomized nor systematic, limiting the capacity to assess the signature's prognostic potential for individual treatment choices. Future research should focus on prospective validation and investigation of the molecular mechanisms that underlie the signature's predictive ability. Overall, this RNA-seq prognostic signature represents a substantial advancement in precision oncology, providing a helpful tool for personalized lung adenocarcinoma treatment. 
